Q4 2018 Vanda Pharmaceuticals Inc Earnings Call
שיחת ועידה Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc Conference call will be held on 13/02/2019. During the earnings conference call's session Vanda Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Vanda Pharmaceuticals Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
Vanda Pharmaceuticals Inc. (we, Vanda or the Company) is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. Vanda commenced its operations in 2003 and our product portfolio includes: * HETLIOZ®(tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24), was approved by the U.S. Food and Drug Administration (FDA) in January 2014 and launched commercially in the U.S. in April 2014. In July 2015, the European Commission (EC) granted centralized marketing authorization with unified labeling for HETLIOZ® for the treatment of Non-24 in totally blind adults. This authorization is valid in the 28 countries that are members of the European Union, as well as European Economic Area members Iceland, Liechtenstein and Norway.קרא עוד שיחת ועידה